Edwards Lifesciences Corporation (EW) has experienced various shifts in its stock holdings. Retirement systems and banks like Public Employees Retirement System of Ohio, Bank Pictet & Cie, and Swedbank AB have sold their shares, while others like Randolph Co Inc, Czech National Bank, Collective Advisors LLC and Assenagon Asset Management have increased their stake. There are mixed ratings for EW, with Wall Street Zen upgrading EW to strong-buy and analysts suggesting a $86.26 average price target.
The corporation welcomed updated ESC/EACTS Guidelines for severe Aortic Stenosis (AS), potentially indicative of their commitment to innovation. However, FTC is blocking EW's acquisition of JenaValve, which might pose regulatory challenges. Despite that, EW reported Q2 2025 earnings outlining strong sales growth. EW also announced a $500 Million Accelerated Share Repurchase. Current investment sentiment appears to be cautiously optimistic, tempered with a keen eye on the company's debt management and regulatory environment.
Edwards Lifesciences Corp EW News Analytics from Mon, 02 Dec 2024 08:00:00 GMT to Fri, 26 Sep 2025 10:07:12 GMT - Rating 2 - Innovation 4 - Information 7 - Rumor -1
